Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Bipolar disorder drugs & treatment industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug class trends
2.1.4 Route of administration trends
2.1.5 Mechanism of action trends
Chapter 3 Bipolar Disorder Drugs & Treatment Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing awareness on mental health
3.2.1.2 Increasing prevalence of bipolar disorders
3.2.1.3 Rising government support
3.2.1.4 Technological advancements
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with bipolar drugs
3.2.2.2 Misdiagnosis of bipolar disorder
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By route of administration
3.3.3 By mechanism of action
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Types of bipolar disorder
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategic outlook matrix
Chapter 5 Bipolar Disorder Drugs & Treatment Market Size and Forecast, By Drug Class (USD Million)
5.1 Key trends, by drug class
5.2 Mood Stabilizer
5.3 Anticonvulsants
5.4 Anti-Psychotic Drugs
5.5 Anti-Depressant Drugs
5.6 Anti-Anxiety Drugs
Chapter 6 Bipolar Disorder Drugs & Treatment Market Size and Forecast, By Route of Administration (USD Million)
6.1 Key trends, by route of administration
6.2 Oral
6.3 Parenteral
6.4 Other route of administrations
Chapter 7 Bipolar Disorder Drugs & Treatment Market Size and Forecast, By Mechanism of Action (USD Million)
7.1 Key trends, by mechanism of action
7.2 Selective Serotonin Reuptake Inhibitor
7.3 Serotonin Norepinephrine Reuptake Inhibitor,
7.4 Tricyclic Antidepressant Drug
7.5 Beta Blockers
7.6 Others
Chapter 8 Bipolar Disorder Drugs & Treatment Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Switzerland
8.3.8 Netherlands
8.3.9 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Thailand
8.4.7 Indonesia
8.4.8 Vietnam
8.4.9 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Chile
8.5.6 Peru
8.5.7 Rest of Latin America
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Israel
8.6.5 Rest of MEA
Chapter 9 Company Profiles
9.1 GlaxoSmithKline (GSK)
9.2 Pfizer Inc
9.3 Eli Lily
9.4 AbbVie Inc.
9.5 Otsuka Holdings Co.Ltd
9.6 AstraZeneca
9.7 Novartis AG
9.8 Janssen Pharmaceuticals
9.9 Validus Pharmaceuticals LLC
9.10 Sunovion Pharmaceuticals Inc.
